GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celyad Oncology SA (XBRU:CYAD) » Definitions » Accumulated other comprehensive income (loss)

Celyad Oncology (XBRU:CYAD) Accumulated other comprehensive income (loss) : €269.80 Mil (As of Jun. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Celyad Oncology Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Celyad Oncology's Accumulated other comprehensive income (loss) for the quarter that ended in Jun. 2023 was €269.80 Mil.

Celyad Oncology's quarterly Accumulated other comprehensive income (loss) increased from Jun. 2022 (€268.80 Mil) to Dec. 2022 (€269.36 Mil) and increased from Dec. 2022 (€269.36 Mil) to Jun. 2023 (€269.80 Mil).

Celyad Oncology's annual Accumulated other comprehensive income (loss) increased from Dec. 2020 (€222.17 Mil) to Dec. 2021 (€267.73 Mil) and increased from Dec. 2021 (€267.73 Mil) to Dec. 2022 (€269.36 Mil).

Celyad Oncology Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Celyad Oncology's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celyad Oncology Accumulated other comprehensive income (loss) Chart

Celyad Oncology Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Accumulated other comprehensive income (loss)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.67 28.18 222.17 267.73 269.36

Celyad Oncology Quarterly Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Jun23
Accumulated other comprehensive income (loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 267.73 268.16 268.80 269.36 269.80

Celyad Oncology Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

Celyad Oncology Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Celyad Oncology's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Celyad Oncology (XBRU:CYAD) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celyad Oncology SA (XBRU:CYAD) » Definitions » Accumulated other comprehensive income (loss)
Comparable Companies
XBRU:ALIMG XBRU:BIOS XBRU:OXUR OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX BGNE SZSE:300122 ALNY OCSE:GMAB XKRX:068270 BMRN XBRU:UCB
Traded in Other Exchanges
1C0:Germany
Address
Rue Edouard Belin 2, Axis Business Park, Brabant Wallon, Mont-Saint-Guibert, BEL, 1435
Website
https://www.celyad.com
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of innovative technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments.

Celyad Oncology (XBRU:CYAD) Headlines

No Headlines